A Phase 1, Open-label, Single-site, Multi-part, Non-randomized, Parallel-group Study to Assess the Relative Bioavailability of BMS-986435 Tablet Formulations (Parts 1 & 2) and Food Effect on the Selected BMS-986435 Tablet Formulation (Part 3) in Healthy Adult Participants
Latest Information Update: 10 Mar 2026
At a glance
- Drugs MYK 224 (Primary)
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 04 Mar 2026 Status changed from active, no longer recruiting to recruiting.
- 27 Jan 2026 Status changed from recruiting to active, no longer recruiting.
- 14 Nov 2025 Status changed from not yet recruiting to recruiting.